Equine hyperimmune serum protects mice against Clostridium difficile spore challenge

Journal of Veterinary Science

Volumn 15, Issue 2, 2014, Pages 249-258

  Yan, Weiwei ^a   Shin, Kang Soon ^a   Wang, Shih Jon ^a,b   Xiang, Hua ^a,c   Divers, Thomas ^a   Mcdonough, Sean ^a   Bowman, James ^d   Rowlands, Anne ^d   Akey, Bruce ^a   Mohamed, Hussni ^a   Chang, Yung Fu ^a  

^a Department of Obstetrics Gynecology   (United States)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^c INSTITUTE OF ANIMAL SCIENCE   (China)

^d Lake Immunogenics Inc   (United States)

Author keywords

Clostridium difficile; Colitis; Equine; Immunotherapy

Indexed keywords

ANTISERUM; BACTERIAL PROTEIN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL; BACTERIAL SPORE; BLOOD; C57BL MOUSE; CLOSTRIDIUM INFECTIONS; FEMALE; HORSE; HORSE DISEASES; IMMUNOLOGY; MICROBIOLOGY; MOUSE; PASSIVE IMMUNIZATION; PEPTOCLOSTRIDIUM DIFFICILE; VETERINARY;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROTOXINS; FEMALE; HORSE DISEASES; HORSES; IMMUNE SERA; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED C57BL; SPORES, BACTERIAL;

EID: 84902356035     PISSN: 1229845X     EISSN: 1976555X     Source Type: Journal    
DOI: 10.4142/jvs.2014.15.2.249     Document Type: Article

References (40)

1. Ananthakrishnan AN. Clostridium difficile infection:epidemiology, risk factors and management. Nat RevGastroenterol Hepatol 2011, 8, 17-26.
2. Arroyo LG, Staempfli H, Weese JS. Molecular analysis of Clostridium difficile isolates recovered from horses with diarrhea. Vet Microbiol 2007, 120, 179-183.
3. Artiushin S, Timoney JF, Fettinger M, Fallon L, Rathgeber R. Immunisation of mares with binding domains of toxins A and B of Clostridium difficile elicits serum and colostral antibodies that block toxin binding. Equine Vet J 2013, 45, 476-480.
4. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002, 346, 334-339.
5. Båverud V. Clostridium difficile diarrhea: infection control in horses.Vet Clin North Am Equine Pract 2004, 20, 615-630.
6. Båverud V, Franklin A, Gunnarsson A, Gustafsson A, Hellander-Edman A. Clostridium difficile associated with acute colitis in mares when their foals are treated with erythromycin and rifampicin for Rhodococcus equi pneumonia. Equine Vet J 1998, 30, 482-488.
7. Carman RJ, Stevens AL, Lyerly MW, Hiltonsmith MF, Stiles BG, Wilkins TD. Clostridium difficile binary toxin (CDT) and diarrhea. Anaerobe 2011, 17, 161-165.
8. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. A mouse model of Clostridium difficile-associated disease. Gastroenterology 2008, 135, 1984-1992.
9. Corthier G, Muller MC, Wilkins TD, Lyerly D, L'Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun 1991, 59, 1192-1195.
10. Ehrich M, Van Tassell RL, Libby JM, Wilkins TD. Production of Clostridium difficile antitoxin. Infect Immun 1980, 28, 1041-1043.
11. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012, 30, 4307-4309.
12. Forbes G, Church S, Savage CJ, Bailey SR. Effects of hyperimmune equine plasma on clinical and cellular responses in a low-dose endotoxaemia model in horses. Res Vet Sci 2012, 92, 40-44.
13. Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 2009, 27, 3598-3604.
14. Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel MA, Monath TP, Thomas WD Jr. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 1999, 67, 527-538.
15. Giguère S, Gaskin JM, Miller C, Bowman JL. Evaluation of a commercially available hyperimmune plasma product for prevention of naturally acquired pneumonia caused by Rhodococcus equi in foals. J Am Vet Med Assoc 2002, 220, 59-63.
16. Greenberg RN, Marbury TC, Foglia G, Warny M. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012, 30, 2245-2249.
17. Johnson S, Gerding DN, Janoff EN. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 1992, 166, 1287-1294.
18. Keessen EC, Gaastra W, Lipman LJ. Clostridium difficile infection in humans and animals, differences and similarities. Vet Microbiol 2011, 153, 205-217.
19. Kelly CP, Pothoulakis C, Vavva F, Castagliuolo I, Bostwick EF, O'Keane JC, Keates S, LaMont JT. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother 1996, 40, 373-379.
20. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998, 66, 2018-2025.
21. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467, 711-713.
22. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000, 342, 390-397.
23. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010, 28, 965-969.
24. Lyerly DM, Bostwick EF, Binion SB, Wilkins TD. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 1991, 59, 2215-2218.
25. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 2005, 54, 101-111.
26. Mulligan ME, Miller SD, McFarland LV, Fung HC, Kwok RY. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 1993, 16 (Suppl 4), S239-244.
27. O'Brien JB, McCabe MS, Athié-Morales V, McDonald GS, Ní Eidhin DB, Kelleher DP. Passive immunisation of hamsters against Clostridium difficile infection using antibodies to surface layer proteins. FEMS Microbiol Lett 2005, 246, 199-205.
28. Oberli MA, Hecht ML, Bindschädler P, Adibekian A, Adam T, Seeberger PH. A possible oligosaccharideconjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol 2011, 18, 580-588.
29. Ostrowski SR, Kubiski SV, Palmero J, Reilly CM, Higgins JK, Cook-Cronin S, Tawde SN, Crossley BM, Yant P, Cazarez R, Uzal FA. An outbreak of equine botulism type A associated with feeding grass clippings. J Vet Diagn Invest 2012, 24, 601-603.
30. Peláez T, Alcalá L, Alonso R, Rodríguez-Créixems M, García-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002, 46, 1647-1650.
31. Roberts A, McGlashan J, Al-Abdulla I, Ling R, Denton H, Green S, Coxon R, Landon J, Shone C. Developmentand evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun 2012, 80, 875-882.
32. Ruby R, Magdesian KG, Kass PH. Comparison of clinical, microbiologic, and clinicopathologic findings in horses positive and negative for Clostridium difficile infection. J Am Vet Med Assoc 2009, 234, 777-784.
33. Saito T, Kimura S, Tateda K, Mori N, Hosono N, Hayakawa K, Akasaka Y, Ishii T, Sumiyama Y, Kusachi S, Nagao J, Yamaguchi K. Evidence of intravenous immunoglobulin as a critical supportive therapy against Clostridium difficile toxin-mediated lethality in mice. J Antimicrob Chemother 2011, 66, 1096-1099.
34. Scaria J, Ponnala L, Janvilisri T, Yan W, Mueller LA, Chang YF. Analysis of ultra low genome conservation in Clostridium difficile. PLoS One 2010, 5, e15147.
35. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol 2008, 190, 2505-2512.
36. Tillotson GS, Tillotson J. Clostridium difficile-a moving target. F1000 Med Rep 2011, 3, 6.
37. Torres JF, Lyerly DM, Hill JE, Monath TP. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 1995, 63, 4619-4627.
38. Van Dissel JT, de Groot N, Hensgens CM, Numan S, Kuijper EJ, Veldkamp P, Van't Wout J. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 2005, 54, 197-205.
39. Van Nispen Tot Pannerden CM, Verbon A, Kuipers EJ. Recurrent Clostridium difficile infection: what are the treatment options? Drugs 2011, 71, 853-868.
40. Yan W, Faisal SM, McDonough SP, Divers TJ, Barr SC, Chang CF, Pan MJ, Chang YF. Immunogenicity and protective efficacy of recombinant Leptospira immunoglobulin-like protein B (rLigB) in a hamster challenge model. Microbes Infect 2009, 11, 230-237.